Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01885936 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01885936 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 16 participants.
The verdict
NCT01885936, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
In this study the study team proposes to investigate the efficacy of albuterol on motor function of individuals with Late Onset Pompe Disease (LOPD) who are receiving enzyme replacement therapy, given albuterol was well-tolerated in patients with Late Onset Pompe Disease.
Interventions
- DRUG Placebo
- DRUG Albuterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-06 |
| Est. Completion | 2016-12-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01885936
The ClinicalTrials.gov registry entry for NCT01885936 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01885936 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01885936 about?
NCT01885936 is a clinical study titled "Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease". In this study the study team proposes to investigate the efficacy of albuterol on motor function of individuals with Late Onset Pompe Disease (LOPD) who are receiving enzyme replacement therapy, given albuterol was well-tolerated in patients with Late Onset Pompe Disease.
What is the current status of trial NCT01885936?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2013-06. Estimated completion is 2016-12-16.
What interventions are being tested in trial NCT01885936?
The interventions under investigation include: Placebo (DRUG), Albuterol (DRUG).
Who is sponsoring clinical trial NCT01885936?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.